SkylineDx presents first prospective validation data Merlin Test at EADO 2022

ROTTERDAM, Netherlands and SAN DIEGO, April 21, 2022 /PRNewswire/ — Today, SkylineDx presents new data showing that their Merlin Test was able to prospectively reduce >37% of surgeries in a non-interventional study for newly diagnosed melanoma patients2. The Merlin Test identifies…

Click here to view original post